The Official Journal of EuroPCR and the European Association of Percutaneous Coronary Interventions (EAPCI)
Volume 19 Number 4
In this issue of EuroIntervention, we have a debate on in-hospital PCSK9 inhibitor initiation. In coronary interventions, the effects of alirocumab on coronary haemodynamics as assessed by quantitative flow ratio and percentage diameter stenosis by three-dimensional quantitative coronary angiography; the five-year clinical results of the EBC TWO Trial; posterior pericardiotomy for postoperative atrial fibrillation; a novel IVUS-OCT hybrid; and the NEOMINDSET Trial, SAPT with a potent P2Y12 inhibitor compared with traditional DAPT for 12 months. In interventions for valvular disease and heart failure: Evolut-in-Evolut redo-TAVI vs SAPIEN 3-in-Evolut redo-TAVI; TAVI in extra-small aortic annuli; the DurAVR transcatheter heart valve; transcatheter tricuspid valve intervention with the Mistral device; and more.